Elebsiran

N/A

Report date: 2026/03/07 20:00:27
NME

Base Information

Drug NameElebsiran
Drug Alias NameVIR-2218ALN-HBV02BRII-835
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceHBsAg inhibitorsAsialoglycoprotein receptor modulators
TargetsHepatitis B Surface AntigensAsialoglycoprotein receptor
Therapy Area/IndicationsRenal InsufficiencyLiver CirrhosisHepatic Insufficiency +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[25] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesVir Biotechnology IncAlnylam Pharmaceuticals IncBrii Biosciences (Shanghai) Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsRenal InsufficiencyLiver CirrhosisHepatic Insufficiency +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A